August J. Troendle Sells 84,093 Shares of Medpace Holdings Inc (MEDP) Stock

Share on StockTwits

Medpace Holdings Inc (NASDAQ:MEDP) CEO August J. Troendle sold 84,093 shares of the stock in a transaction on Friday, February 1st. The stock was sold at an average price of $65.54, for a total value of $5,511,455.22. Following the completion of the sale, the chief executive officer now owns 603,702 shares of the company’s stock, valued at approximately $39,566,629.08. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Shares of Medpace stock opened at $66.51 on Wednesday. The stock has a market cap of $2.41 billion, a PE ratio of 43.76, a PEG ratio of 1.44 and a beta of 1.76. The company has a quick ratio of 0.66, a current ratio of 0.66 and a debt-to-equity ratio of 0.25. Medpace Holdings Inc has a twelve month low of $31.75 and a twelve month high of $69.71.

MEDP has been the subject of a number of analyst reports. SunTrust Banks upgraded Medpace from a “hold” rating to a “buy” rating and set a $63.00 price target for the company in a research note on Wednesday, October 31st. They noted that the move was a valuation call. BidaskClub lowered Medpace from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 31st. Zacks Investment Research upgraded Medpace from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research report on Thursday, November 1st. Finally, ValuEngine lowered Medpace from a “buy” rating to a “hold” rating in a research report on Thursday, December 6th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $44.43.

Institutional investors have recently modified their holdings of the company. LS Investment Advisors LLC purchased a new position in shares of Medpace during the fourth quarter valued at about $46,000. State of Alaska Department of Revenue purchased a new position in shares of Medpace during the fourth quarter valued at about $92,000. We Are One Seven LLC purchased a new position in shares of Medpace during the fourth quarter valued at about $130,000. Great West Life Assurance Co. Can grew its position in shares of Medpace by 270.1% during the third quarter. Great West Life Assurance Co. Can now owns 3,331 shares of the company’s stock valued at $200,000 after purchasing an additional 2,431 shares in the last quarter. Finally, Legal & General Group Plc grew its position in shares of Medpace by 78.6% during the third quarter. Legal & General Group Plc now owns 3,436 shares of the company’s stock valued at $206,000 after purchasing an additional 1,512 shares in the last quarter. Hedge funds and other institutional investors own 72.44% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “August J. Troendle Sells 84,093 Shares of Medpace Holdings Inc (MEDP) Stock” was originally posted by Equities Focus and is the property of of Equities Focus. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.equitiesfocus.com/2019/02/06/august-j-troendle-sells-84093-shares-of-medpace-holdings-inc-medp-stock.html.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Featured Story: What is Compound Interest?

Insider Buying and Selling by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply